Costa Panagos Net Worth: Estimate, Sources, and How to Verify

Costa Panagos has an estimated net worth in the range of $10 million to $15 million as of 2026, with the most specific publicly available figure being the $10.8 million estimate from Benzinga, calculated primarily from his reported IQVIA Holdings share ownership. That number is derived from insider-trading filings and reflects equity holdings at a point in time, not total lifetime wealth, so treat it as a floor rather than a ceiling.

Who is Costa Panagos?

Costa Panagos, whose full legal name is Constantinos Panagos, is a Greek-American life-sciences executive with more than 25 years of leadership experience inside the contract research organization (CRO) industry. He built his career at Quintiles, one of the largest CROs in the world, and later held a senior president-level role at IQVIA Holdings (the company formed when Quintiles merged with IMS Health) where he led Research and Development Solutions. He also served as founding CEO of Q2 Solutions, the clinical-laboratory joint venture that Quintiles launched with Quest Diagnostics in 2015. As of early 2025, he was appointed CEO of Syneos Health, a major publicly traded CRO headquartered in the Research Triangle area of North Carolina. His career sits squarely inside the pharmaceutical outsourcing and clinical-trial services world, a sector that generates substantial executive compensation packages tied to base salary, annual incentives, and long-term equity.

Within the Greek diaspora business community, Panagos represents a different path to wealth than the shipping dynasties or entertainment figures more commonly profiled in Greek-heritage financial databases. His fortune is rooted in corporate life sciences, a sector where compensation is largely invisible to the public until SEC filings surface equity transactions.

Costa Panagos net worth: best estimates and current range

The most cited figure comes from Benzinga, which estimated Constantinos Panagos's net worth at $10.8 million as of November 2024, with the page updated again in April 2026. Benzinga's methodology is based on reported share holdings in IQVIA Holdings, derived from SEC Form 4 insider-trading disclosures. GuruFocus offers a similar estimate but explicitly caveats that it assumes no transactions have occurred after September 19, 2023, which is close to his confirmed departure date from IQVIA on September 25, 2023.

A realistic current range sits between $10 million and $15 million. The lower bound reflects the equity-based estimate from insider filings. The upper bound accounts for accumulated cash compensation over a multi-decade executive career, severance, and any investment appreciation since leaving IQVIA, none of which appear in the insider-share calculations. It is possible his total wealth exceeds $15 million when private investments or real estate are factored in, but there is no public documentation to push the estimate meaningfully higher with confidence.

Where the money comes from

Panagos's wealth is built on three overlapping income streams common to senior pharma and CRO executives: base salary and annual bonuses, long-term equity compensation (stock grants and options), and one-time payments tied to role transitions.

• Executive base salary and annual incentives at Quintiles, Q2 Solutions, and IQVIA over roughly 20+ years. C-suite and president-level roles in this sector typically carry base salaries between $500,000 and $1.2 million, plus performance bonuses.
• Equity and stock-based compensation tied to IQVIA Holdings, the publicly traded parent company. These grants vest over time and represent the largest single wealth-building mechanism for most CRO executives. Benzinga's $10.8 million figure is drawn almost entirely from this equity position.
• Severance and transition payments upon his exit from IQVIA in September 2023. The IQVIA proxy statement filed with the SEC documents a severance component of approximately $620,000, which is a confirmed cash payment separate from equity.
• CEO compensation at Syneos Health, which became effective in early 2025. As a publicly traded CRO, Syneos's executive pay packages include salary, performance-linked bonuses, and equity grants that will add to future wealth estimates as new filings emerge.
• Any passive investment income, real estate, or private equity positions, which are not publicly disclosed but are common among executives at this wealth level.

Career milestones and when wealth likely grew

Panagos's career has several inflection points where compensation would have stepped up meaningfully. Mapping these milestones helps explain how someone with no apparent shipping or entertainment background ends up with an eight-figure estimated fortune.

1. Early career at Quintiles: Multi-year tenure at one of the world's largest CROs, building seniority and accumulating equity in a company that later went public. This phase laid the foundation but probably represents the smallest accumulation period.
2. Q2 Solutions CEO role (2015): When Quintiles and Quest Diagnostics launched Q2 Solutions as a joint venture, Panagos was named CEO. Executive leadership at a newly formed clinical-laboratory platform of this scale typically triggers new equity grants, signing bonuses, and a significant salary increase. This is likely the first major wealth-building event.
3. President of R&D Solutions at IQVIA: After the Quintiles-IMS merger created IQVIA, Panagos moved into a president-level role overseeing a business unit responsible for a substantial portion of IQVIA's revenue. IQVIA is publicly traded (NYSE: IQV), and equity grants at this level accumulate and vest over several years. The insider filings on EDGAR (CIK 0001917705) document specific share transactions during this period.
4. Exit from IQVIA (September 25, 2023): His confirmed departure triggered the severance package documented in the 2024 proxy statement. Any unvested equity that accelerated on departure would also have contributed to a lump-sum wealth event.
5. Syneos Health CEO appointment (early 2025): A new top-executive role at a publicly traded company restarts the equity clock. Compensation tables for this role will appear in future Syneos proxy filings and will become a key input for updated net-worth estimates.

Assets and lifestyle indicators

There is limited public information about Panagos's personal assets beyond the equity positions already captured in SEC filings. The Better Business Bureau profile for Q2 Solutions lists a Durham, North Carolina business address, and his executive roles at IQVIA and Syneos Health are both North Carolina-based, suggesting his primary residence is in the Research Triangle area. North Carolina's real-estate market, while significantly lower cost than New York or San Francisco, has seen strong appreciation in the Durham-Raleigh corridor, where senior biotech and pharma executives routinely hold high-value residential properties.

No public records surfaced in the available research confirm specific property ownership, yacht holdings, or private-company stakes. Unlike some Greek diaspora figures whose wealth is tied to tangible, easily valued assets like shipping fleets or real estate portfolios, Panagos's wealth is primarily financial and therefore less visible. His lifestyle indicators are professional rather than conspicuous, consistent with corporate executives in the pharmaceutical outsourcing sector.

What's confirmed vs. what's speculation

This distinction matters more for corporate executives than for celebrities, because the numbers that float around online are often generated by automated tools that only see one slice of the picture.

The $10.8 million figure is credible as a partial estimate, not a complete one. It captures the equity component tied to a specific company at a specific point in time. It does not capture cash savings, real estate equity, private investments, or the compensation he has begun earning at Syneos Health. Treating it as his total net worth understates the probable reality; treating any higher number as fact overstates what can be verified. If you are also wondering about Will Kostakis net worth, the best approach is to compare similar SEC-linked equity and compensation timelines.

How this compares to peers in the Greek diaspora business world

Within the universe of Greek and Greek-American business figures, an estimated $10 to $15 million net worth places Panagos firmly in the successful senior-executive bracket rather than the ultra-high-net-worth tier occupied by shipping families or entertainment entrepreneurs. If you are also tracking similar figures like Costa Gratsos net worth, you can compare how different industries and compensation structures shape the totals people estimate online. Greek diaspora wealth profiles span an enormous range: shipping magnates can hold fortunes in the hundreds of millions, while athletes like Kostas Manolas or Kostas Fortounis have estimated wealth built on club contracts and image rights that are publicly visible through transfer records. Business figures like Costa Gratsos built wealth through close ties to the tanker trade. Panagos's path is more analogous to other corporate Greek-Americans who rose through multinational professional structures, where equity compensation is the primary driver and the money is quieter but real.

How to find updated or verified numbers yourself

If you want to go beyond the estimates on aggregator sites, the primary sources are accessible and free. Here is the practical workflow:

1. Go to SEC EDGAR (sec.gov/cgi-bin/browse-edgar) and search for CIK number 0001917705, or search by name for 'Panagos Constantinos.' This pulls up all Form 4 filings, which document every insider share transaction. These are the raw inputs that Benzinga and GuruFocus use.
2. Review the most recent Form 4 filings to see current share holdings after any sales or grants. Multiply the share count by IQVIA's current stock price (NYSE: IQV) to get an updated equity-only estimate.
3. Look up Syneos Health's most recent proxy statement (DEF 14A) on EDGAR to find Panagos's disclosed compensation package as CEO. This will include base salary, target bonus, and equity grant values, giving a clearer picture of ongoing income.
4. Check IQVIA's 2024 proxy statement (DEF 14A) for the confirmed compensation table that includes his severance. This is the only primary-source cash figure available publicly.
5. Cross-reference any net-worth figure you find online against these filings. If a site claims a number far above the equity-based calculation with no explanation, treat it skeptically.

Net-worth estimates for corporate executives are inherently incomplete because most of their wealth exists in forms that do not require public disclosure: bank accounts, private investments, real estate bought under an LLC, and deferred compensation plans. The SEC filings only reveal the publicly traded equity component. That is why even the most carefully calculated figures should be understood as minimums anchored to what is visible, not as authoritative totals. For a reader using a Greek-wealth reference database, the most intellectually honest framing is: Costa Panagos's documented equity and compensation history supports an estimated net worth of at least $10 million, with total wealth plausibly higher given the scope and duration of his executive career.